Jul 19,2023

HealthTab™ to Integrate CONTOUR®NEXT Family of Blood Glucose Meters to Offer Deeper Diabetes Patient Insights

Avricore Health partners with Ascensia Diabetes Care to integrate CONTOUR®NEXT Blood Glucose Meters into HealthTab, enhancing diabetes patient insights and care in Canada. The partnership’s objective is to support patients and pharmacists in Canada in better managing diabetes by linking the daily blood glucose testing results and pattern history data collected via the CONTOUR®NEXT GEN or CONTOUR®NEXT ONE meter the patient uses to the patient’s HealthTab account. The partnership also seeks to support utilization of each technology by opening discussions related to collaborative communications to ensure patients and pharmacists are able to take advantage of what these data insights offer.

COLLABORATION PARTNERSHIP

#connected device

#bgm

#rpm

View Analyst & Ambassador Comments
Go to original news
Jun 28,2023

Preventing Cervical Cancer with Digital Health

In England alone, around 2,700 women are diagnosed with cervical cancer each year. However, the NHS screening programme saves approximately 5,000 lives annually. One remarkable success story in promoting cervical cancer screenings is the project commissioned by NHS England and North of England CSU. The project used iPLATO's Population Health Service, part of HUMA, to send text message reminders to women who were due for their screening appointment. Through this initiative, attendance rates for cervical cancer screenings increased by 6.3% in London. The project reduced the invite-to-appointment time by 17 days.

PRODUCT

#rpm

View Analyst & Ambassador Comments
Go to original news
Jun 29,2023

Jasper Health Partners with Wellnecity to Bring Digital Oncology Platform to Self-Insured Employers

Jasper Health is thrilled to announce the availability of its platform for Wellnecity self-insured employer clients. The platform aims to revolutionize the way cancer patients and their caregivers receive support by offering one-on-one human-led psychosocial coaching, personalized guidance, and innovative digital planning tools. Wellnecity’s extensive network of self-insured employer clients will now have access to Jasper Health’s ComPass offering tailored for employers that may have a smaller population of covered lives, as well as gig economy employees who may not have access to a cancer care benefit otherwise. Key features of the Jasper Health ComPass offering for Wellnecity includes human-led psychosocial coaching, personalized guidance, and digital planning tools.

COLLABORATION PARTNERSHIP

#institution

#rpm

#coaching

View Analyst & Ambassador Comments
Go to original news
Nov 15,2022

Rimidi Joins Henry Schein Medical SolutionsHub

Rimidi announced today a new distribution agreement with Henry Schein Medical, the U.S. medical business of Henry Schein, Inc. As a result of this new agreement, Rimidi is part of the Henry Schein Medical SolutionsHub, and Henry Schein will offer its clinic, medical group, and health system customers access to Rimidi’s cloud-based software platform, further enhancing efforts to support efficient models of care for chronic disease management. Current clinical use cases of the Rimidi platform include chronic, cardiometabolic conditions, epidemic management, and perioperative care.

COLLABORATION PARTNERSHIP

#institution

#rpm

View Analyst & Ambassador Comments
Go to original news
Aug 30,2022

Boston hospital remotely monitors new moms through Epic app

Boston Medical Center is remotely monitoring new mothers for conditions like postpartum hypertension to keep the women well and out of the hospital. The academic medical center employs the Rimidi care management platform, part of Epic's app store. The hospital is expanding the program to monitor for gestational hypertension, via cellular blood pressure cuffs, and gestational diabetes, through cellular glucometers.

COLLABORATION PARTNERSHIP

#institution

#rpm

View Analyst & Ambassador Comments
Go to original news
Aug 30,2022

Rimidi and Boston Medical Center Release Metrics from Ongoing Remote Monitoring Program for Postpartum Hypertension

Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences and achieve quality objectives, and Boston Medical Center, a private, not-for-profit academic medical center in New England, today released metrics from an ongoing remote patient monitoring program for new moms at high-risk of postpartum hypertension. Boston Medical Center leveraged the Rimidi platform to bring remotely-generated patient data from cellular-connected blood pressure cuffs into their clinical workflow. As part of Epic’s app orchard, Rimidi launches directly within the BMC team’s Epic experience. Resulting from the initial success of Boston Medical Center’s postpartum hypertension program, the center is now expanding the program to include monitoring for gestational hypertension, using cellular blood pressure cuffs and gestational diabetes, using cellular glucometers and FreeStyle Libre Continuous Glucose Monitors.

CLINICAL STUDY

#rpm

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 22,2023

Rimidi Showcases Addition of Glycemic Risk Index to Diabetes Management Platform, Announces Enhanced Integration with Dexcom

Rimidi announced today enhancements to its diabetes management platform, including the addition of Glycemic Risk Index (GRI) as an emerging tool for patient and population outcomes management. The inclusion of CGM data and GRI into Rimidi’s platform and clinical workflows is made possible via an enhanced integration with Dexcom, a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes. Through the collaboration, glycemic control metrics will enable more proactive and personalized management of diabetes across populations to drive better care decisions. This metric can be used to assess how well a patient is doing over time, manage a population and predict outcomes in intervention studies. The composite score is also thought to better correlate with the risk of complications and help identify areas for therapy adjustment.

COLLABORATION PARTNERSHIP

#connected device

#cgm

#rpm

View Analyst & Ambassador Comments
Go to original news
Jun 12,2023

Huma receives multi-condition US FDA 510(k) Class II regulatory clearance for its configurable SaMD disease management platform

Huma Therapeutics, a leading global digital health company, today announced that it has received U.S. Food and Drug Administration (FDA) Class II clearance for its disease-agnostic Software as a Medical Device (SaMD) platform. Achieving Class II clearance means the platform is permitted to monitor patients of all ages with any condition - including paediatrics, and in pregnancy. The platform is also device-agnostic and can integrate with external third-party devices such as heart rate and blood sugar monitors, as well as smart inhalers, enhancing its capabilities and versatility.

REGULATORY FDA

#rpm

View Analyst & Ambassador Comments
Go to original news
Feb 24,2022

The majority of patients find remote care helpful. Clinicians can benefit from patient use, too.

Survey results from a recent Propeller Health study to be presented at the 2022 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting found that the majority of patients (68.7%) find their use of remote care helpful. Of the 441 patients surveyed, about one third of patients reported that they connected with their asthma providers through video visits and messaging services. In another Propeller Health study to be presented at the AAAAI Annual Meeting, Propeller found that monthly surveys conducted through its digital health app may be a feasible way to capture user-reported acute care events, potentially supporting early prediction of symptom worsening in patients with asthma.

CLINICAL STUDY

#rpm

View Analyst & Ambassador Comments
Go to original news
Sep 09,2021

Propeller Health research to be showcased at ERS International Congress 2021

The European Respiratory Society (ERS) International Congress, which took place virtually between September 5-8, 2021, is an annual event that brings together the world’s respiratory experts to present and discuss the latest scientific and clinical advances in the field of respiratory medicine. This year, the ERS accepted four abstracts authored by Propeller and its research partners ResMed and Novartis. The summary of the abstracts from the studies are announced by Propeller Health in advance.

CLINICAL STUDY

#mobile app

#rpm

#connected device

View Analyst & Ambassador Comments
Go to original news
Subscribe to RPM